<DOC>
	<DOCNO>NCT00991055</DOCNO>
	<brief_summary>The purpose trial study efficacy safety pioglitazone add combination therapy sulfonylurea plus metformin placebo patient type 2 diabetes .</brief_summary>
	<brief_title>Comparison Efficacy Safety Between Pioglitazone Placebo Added Combination Therapy Type 2 Diabetes</brief_title>
	<detailed_description>Pioglitazone hydrochloride , thiazolidinedione compound , new therapeutic agent treatment type 2 diabetes reduces insulin resistance enhance insulin action skeletal muscle , liver , adipose tissue . In study diabetes , pioglitazone reduce hyperglycemia , hyperinsulinemia , hypertriglyceridemia characteristic insulin-resistant state . The metabolic change induce pioglitazone result increase responsiveness insulin-dependent tissue observe numerous model insulin resistance . In present randomize , double-blind , parallel study , aim compare efficacy safety pioglitazone add combination therapy sulfonylurea plus metformin sulfonylurea plus metformin treatment type 2 diabetic patient .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Male Female , Aged &gt; 25 year diagnose type 2 diabetes least 3 month study entry . 2 . Subjects take sulfonylurea plus metformin therapy least 3 month study entry . 3 . Subjects take daily Metformin 500~2000mg tolerable dosage sulfonylurea ( usage dose glimepiride ≧4mg ; dose Gliclazide≧160mg ; dose Glipizide ≧20mg ; dose glyburide≧4mg ) least 1 month . 4 . Those subject HbA1C historical level 7.0 % 11.0 % within 3 month prior study entry . 5 . BMI 2035 kg /m2 . 6 . Each subject must level understanding sufficient agree test examination require protocol must sign informed consent document . 7 . Subjects stable diet control least 1 month study entry . 8 . Subjects willing stick current diet sulfonylurea plus metformin treatment plan trial . 1 . Pregnant woman lactate mother . 2 . Type 1 DM ( IDDM ) , diabetes cause pancreas damage、secondary form diabetes , i.e. , Cushing 's syndrome acromegaly . 3 . A history acute metabolic complication within 3 month study entry , i.e. , ketoacidosis hyperosmolar state ( coma ) . 4 . There significant macrovascular complication ( i.e . unstable angina acute myocardial infarction ) renal impairment ( serum creatinine high 1.5 mg/dL ) . 5 . Have know allergy pioglitazone . 6 . Other medication take use instituted study entry , agent interfere study evaluation , include oral antidiabetic agent corticosteroid , allow .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>